divergent-paired related homeobox pseudogene 2Genealiases: []
Q-omics provides the consensus-scored DPRXP2 profile across patient tissues and cancer cell-line models. DPRXP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DPRXP2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, DPRXP2 RNA expression shows 7,061 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, KICH, and STAD as cancer lineages where DPRXP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPRXP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPRXP2 survival associations across molecular data types. DPRXP2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPRXP2 RNA expression–survival associations across cancer types. High DPRXP2 expression shows unfavorable associations in UVM, KICH, KIRC and BRCA, but favorable associations in THCA and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DPRXP2 RNA expression.
This table summarizes DPRXP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for DPRXP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPRXP2 shows lower tumor expression in KICH, LUSC and PRAD and higher tumor expression in BRCA, UCEC and THCA. The KICH box plot shows higher DPRXP2 RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p < 0.001).
This table shows molecular features associated with DPRXP2 in patient tissues and cancer cell lines. In patient samples, DPRXP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
